60 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
duties; (iv) acts or omissions which bring the reputation of the Company into material disrepute; (v) any act or omission by Executive aiding or abetting
8-K
EX-10.1
t3h 7uqgiodzhe7hrwa9
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.4
7ws4 jgrun
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
b2zdv i6h1z62h0
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
vdefoz9wuj0igzr
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
3wdp1s92 ca1chfo2g1
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
mmddsznq7qfn de
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
ul5i7tk
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.01
a2c11eoywymsgsvs
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am